Citigroup Maintains Hold Rating On Acorda Therapeutics (ACOR)
Analysts at Citigroup have recommended that investors ‘Hold’ for Acorda Therapeutics (NASDAQ: ACOR). The target price for the biopharmaceutical company is at $39.00.
Analysts are positive about the launch of Ampyra, an Acorda product, which has received rosy reviews from the medical community. However, the demand backlog on Ampyra is a point of concern, but Acorda is working on it.
Additionally, Acorda received a non-final rejection on one of its 24 filed patents. Acorda, on the other hand, says that the rejection is routine and that they would reply back in 6 months.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.